MarketCap
Senseonics Holdings SENS
$ 10.34
3.66%
Facebook
X
Telegram
Senseonics Holdings Interest Expense | SENS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Senseonics Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23 K | 59 K | 11.1 M | 18.7 M | 16.7 M | 16.2 M | 11.8 M | 8.28 M | 3.1 M | 1.6 M | 1.1 M | 191 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | -23 K | 7.4 M |
Quarterly Interest Expense Senseonics Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -149 K | -37 K | 6 K | -6 K | -17 K | - | -6 K | -1 K | 18 K | - | 15 K | 2.31 M | 4.65 M | - | 4.8 M | 4.51 M | 4.49 M | - | 4.24 M | 4.03 M | 4.06 M | - | 3.63 M | 3.56 M | 4.37 M | - | -638 K | 1.96 M | 2.03 M | - | 2.17 M | 2.24 M | 1.77 M | - | 915 K | 767 K | 684 K | - | 502 K | 268 K | 276 K | - | 266 K | 265 K | 67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.8 M | -638 K | 1.66 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
367 | $ 2.46 | 0.36 % | $ 7.17 M |  USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 61.37 | 13.0 % | $ 3.27 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 79.37 | 0.12 % | $ 3.71 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.15 | 4.55 % | $ 1.53 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 35.19 | 0.89 % | $ 1.02 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 223.77 | 0.95 % | $ 159 B | USA |
 |
DexCom
DXCM
|
177 M | $ 87.47 | 0.21 % | $ 34.1 B | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 21.55 | 1.32 % | $ 663 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 176.45 | 0.08 % | $ 22.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 173.9 | 6.1 % | $ 13.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
41.6 M | $ 513.39 | 0.07 % | $ 41.3 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 275.02 | 2.67 % | $ 47.3 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 308.95 | 1.47 % | $ 25.7 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 99.72 | 0.01 % | $ 6.73 B | USA |
 |
Biodesix
BDSX
|
7.72 M | $ 29.4 | 0.38 % | $ 222 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 620.59 | 0.56 % | $ 17.9 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 519.15 | 1.8 % | $ 31.3 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.14 | 3.24 % | $ 383 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 5.93 | 2.0 % | $ 4.67 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 19.56 | 6.54 % | $ 2.51 B | USA |
 |
Neogen Corporation
NEOG
|
24.1 M | $ 13.66 | 0.66 % | $ 2.97 B | USA |
 |
Syneos Health
SYNH
|
82.4 M | - | - | $ 4.46 B | USA |
 |
Natera
NTRA
|
4.07 M | $ 408.79 | 4.61 % | $ 55.9 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.64 | 0.29 % | $ 1.23 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.78 | 1.09 % | $ 90.2 K | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
32.1 M | $ 71.31 | 0.04 % | $ 5.36 B | USA |
 |
Renalytix AI plc
RNLX
|
249 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
Sotera Health Company
SHC
|
8.55 M | $ 18.45 | 0.87 % | $ 5.24 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 2.82 | 0.21 % | $ 186 M | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 6.95 | 0.68 % | $ 2.5 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 184.03 | 16.11 % | $ 11 B | USA |
 |
VolitionRx Limited
VNRX
|
-1.76 M | $ 0.25 | 2.9 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
14.3 M | $ 430.3 | 2.31 % | $ 25.6 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Exagen
XGN
|
2.34 M | $ 8.74 | 2.22 % | $ 188 M | USA |
 |
Psychemedics Corporation
PMD
|
26 K | - | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
-495 K | - | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
1.19 M | - | - | $ 1.49 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Quotient Limited
QTNT
|
11.6 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.69 | 0.29 % | $ 9.2 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-30 K | $ 18.0 | 19.4 % | $ 194 M |  China |
 |
Bioventus
BVS
|
-1.45 M | $ 13.52 | 0.07 % | $ 901 M | USA |